Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T8730 |
BMS986260
|
TGF-beta/Smad | Stem Cells |
BMS986260是一种口服有活力的选择性TGFβR1抑制剂,是免疫肿瘤学药物。它能够抑制 MINK 和 NHLF 细胞系中 TGFβ 介导的 pSMAD2/3 核转位,IC50值分别为 350 nM 和 190 nM。它对 TGFβR1 的选择比 TGFβR2 同功酶高。 | |||
T69851 |
Riminkefon
|
||
Riminkefon 是κ 阿片受体的激动剂。 | |||
T0860L |
Mefloquine
Ro215998,WR 142490,Ro-215998,氟甲喹羟哌啶,Lariam,Ro 215998 |
Others | Others |
Mefloquine (Ro 215998) 是一种喹啉抗疟药,是一种抗 SARS-CoV-2 进入抑制剂。 Mefloquine 也是一种 K+ 通道 (KvQT1/minK) 拮抗剂,IC50 为 ~1 μM。它可用于疟疾、系统性红斑狼疮和癌症研究。 | |||
T0860 |
Mefloquine hydrochloride
Mefloquin hydrochloride,Mefloquine HCl,盐酸甲氟喹 |
Potassium Channel; SARS-CoV; Reactive Oxygen Species; Parasite; Autophagy | Autophagy; Immunology/Inflammation; Membrane transporter/Ion channel; Metabolism; Microbiology/Virology; NF-κB |
Mefloquine hydrochloride (Mefloquin hydrochloride) 是喹啉抗疟药,是抗 SARS-CoV-2进入抑制剂,可研究疟疾、系统性红斑狼疮和癌症。它也是 K+通道(KvQT1/minK) 拮抗剂,IC50约为 1 μM。 | |||
T33945 |
PF-06260933 HCl
PF06260933 dihydrochloride,PF-06260933 dihydrochloride,PF 06260933 dihydrochloride |
||
PF-06260933 Dihydrochloride is a MAP4K4 (HGK) inhibitor (IC50 = 140 nM). It can improve the fasting hyperglycemia in mice. In addition, it inhibited Mink and Tnik (IC50 values of 8 and 13 nM, respectively). | |||
T36016 | PF 06260933 dihydrochloride | ||
MAP4K4 (HGK) inhibitor (IC50 = 140 nM). Also inhibits MINK and TNIK (IC50 values are 8 and 13 nM, respectively). Improves fasting hyperglycemia in mice. Orally active. Ammirati et al (2015) Discovery of an in vivo tool to establish proof-of-concept for MAP4K4-based antidiabetic treatment. ACS Med.Chem.Lett. 6 1128 PMID:26617966 |